Novartis Pharmaceuticals is evaluating 225Ac-PSMA-617 in the phase I trial AcTION (NCT04597411) (not to be confused with ACTION, NCT05567770), which is enrolling 60 patients with PSMA-positive prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.